BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Remidio's Medios AI shows promise for referable glaucoma

08 July 2022 | News

The process requires no Internet for inferencing



Remidio Innovative Solutions, together with Aravind Eye Hospital (AEH), Pondicherry, and Narayana Nethralaya (NN), Bangalore, announced the results of a clinical trial that can help the detection of referable glaucoma.

The integrated solution provides an instant report in contexts where there are no specialists. It consists of Remidio's Fundus on Phone, a retinal imaging device that captures images of the retina without pupil dilation, and Remidio's Medios Referable Glaucoma AI, an integrated offline AI algorithm that requires no Internet for inferencing.

The Medios Referable Glaucoma AI looks beyond the cup-to-disc ratio and detects structural changes in the optic nerve head and surrounding retinal nerve fibre layer. These are critical regions typically assessed by glaucoma specialists during a clinical examination along with an expensive device called Optical Coherence Tomography.